LYPD9P

Across TCGA pan-cancer cohorts, LYPD9P RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of LYPD9P’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where LYPD9P RNA is repressed in tumor relative to normal tissue. In most cancer types LYPD9P is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

KIRC, KICH, and THCA are the cancer types where LYPD9P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LYPD9P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	III,IV	−0.457	<.001	12	view →
KICH	All	III,IV	−0.697	<.001	11	view →
THCA	All	All	−0.155	.002	3	view →
UCEC	All	IV	+0.440	.031	2	view →
LIHC	All	All	+0.376	.003	2	view →
BRCA	All	III,IV	−0.105	.022	2	view →
COAD	All	II,III,IV	−0.049	.044	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

LYPD9P–KIRC

Open the KIRC breakdown →